---
title: "宜明昂科-B：IMM0306 治療濾泡性淋巴瘤的 III 期臨牀試驗申請"
description: "宜明昂科-B 已向中國國家藥監局提交 IMM0306 III 期臨牀試驗申請。IMM0306 是一種靶向 CD47 和 CD20 的雙特異性分子，全球首個進入臨牀階段的此類分子。該藥物通過抑制 CD47-SIRPα相互作用，增強巨噬細胞和 NK 細胞的活性，有效消除惡性 B 細胞，降低毒性，改善治療效果。公司擁有 IMM0306 的全球知識產權及商業化權利。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/259374214.md"
published_at: "2025-09-29T15:01:03.000Z"
---

# 宜明昂科-B：IMM0306 治療濾泡性淋巴瘤的 III 期臨牀試驗申請

> 宜明昂科-B 已向中國國家藥監局提交 IMM0306 III 期臨牀試驗申請。IMM0306 是一種靶向 CD47 和 CD20 的雙特異性分子，全球首個進入臨牀階段的此類分子。該藥物通過抑制 CD47-SIRPα相互作用，增強巨噬細胞和 NK 細胞的活性，有效消除惡性 B 細胞，降低毒性，改善治療效果。公司擁有 IMM0306 的全球知識產權及商業化權利。

智通財經 APP 訊，宜明昂科-B(01541) 發佈公告，本集團已向中國國家藥品監督管理局 (國家藥監局) 藥品審評中心提交 IMM0306 III 期臨牀試驗的申請。

由本集團獨立研發的 IMM0306 是一種靶向分化簇 47(CD47) 及分化簇 20(CD20) 的雙特異性分子，是全球首個進入臨牀階段的 CD47 和 CD20 雙靶向雙特異性分子。 IMM0306 透過抑制 CD47-SIRPα相互作用來阻斷 “別吃我” 訊號，增強 Fc-FcɣRIIa 和 Fc-FcɣRIIIa 相互作用來激活巨噬細胞和 NK 細胞，並優先結合 CD20 而非 CD47，以有效消除惡性 B 細胞，同時將毒性降至最低，從而可改善治療效果。

截至本公告日期，本集團擁有 IMM0306 的全球知識產權及商業化權利。

### Related Stocks

- [01541.HK - 宜明昂科-B](https://longbridge.com/zh-HK/quote/01541.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Immuneonco Biopharmaceuticals Wins CDE Approval for Phase III Trial of IMM0306 in Follicular Lymphoma | Immuneonco Biopharmaceuticals has received approval from the Center for Drug Evaluation for a Phase III trial of IMM0306 | [Link](https://longbridge.com/zh-HK/news/267625269.md) |
| ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment | ImmuneOnco Biopharmaceuticals has completed enrollment of 104 patients in a Phase III trial for IMM01 (Timdarpacept) tar | [Link](https://longbridge.com/zh-HK/news/273219066.md) |
| Elicera Therapeutics Reports Complete Remission in CARMA Lymphoma Study with ELC-301 Therapy | Elicera Therapeutics AB has reported that four out of six patients in its Phase I/IIa CARMA study achieved complete meta | [Link](https://longbridge.com/zh-HK/news/275613048.md) |
| CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial | CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II clinical trial of its t | [Link](https://longbridge.com/zh-HK/news/276018493.md) |
| 17:28 ETINTA Annual Meeting Registration Surpasses 6,000, Attracting Stellar Speaker Roster | The International Trademark Association (INTA) announces that its 148th Annual Meeting, scheduled for May 2–6, 2026, in  | [Link](https://longbridge.com/zh-HK/news/275668932.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。